A new study has demonstrated the efficacy of ADVOS organ support therapy in successfully treating COVID-19 patients.
ADVOS, the new blood purification procedure from ADVITOS, works to rapidly normalise acid-base imbalance – a major contributor to mortality in COVID-19 patients. In a study evaluating the therapy as a treatment option for COVID-19 patients, researchers found that the procedure can positively impact the treatment of critically ill COVID-19 patients.
The study has been published in the journal Artificial Organs.
Impaired oxygenation is the most common clinical presentation in COVID-19 patients, however some of them also develop problems with carbon dioxide removal. This contributes to acid-base imbalance, which is one of the strongest risk factors for critically ill patients.
ADVOS procedure supports main organs of acid-base balance
The mortality rate of COVID-19 patients with multi-organ failure is high, especially when the main detoxification organs of liver, lung, and kidney have limited function. These three organs are also the main organs to maintain acid-base balance in the physiological range.
The ADVOS (ADVanced Organ Support) procedure offers a four-in-one therapy, providing combined multi-organ support of the liver, lungs, kidneys, and acid-base balance. Through the direct acid removal of the ADVOS procedure, all three organs can be directly supported for the normalisation of the acid-base balance.
Study demonstrates therapy success
To assess the ability of the ADVOS procedure to support the role of the lungs in acid-base balance, a study was conducted by researchers from the II Medical Clinic of the Klinikum rechts der Isar of the Technical University of Munich. The aim of the study was to evaluate the ADVOS system when used to treat predominantly elderly COVID-19 patients with multiple organ failure and problems with carbon dioxide removal.
For the patients in the study, rapid correction of acid-base balance and continuous carbon dioxide removal were achieved during ADVOS treatments. In addition, a significant normalisation of blood pH was realised after the first ADVOS treatment.
Over the treatment period, it was thus possible to rapidly normalise one of the strongest risk factors for increased mortality in COVID-19 patients with acute respiratory distress syndrome and multiple organ failure. Researchers concluded that the study demonstrates that the ADVOS therapy can positively impact the treatment of critically ill COVID-19 patients.
